Trial Profile

Registrational trial of SRG-514 in triple-negative breast cancer patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketorolac (Primary)
Indications Solid tumours; Triple negative breast cancer
Focus Registrational; Therapeutic Use

Most Recent Events

21 Feb 2026 New trial record
12 Feb 2026 According to a Surge therapeutics media release, the company expects to initiate a registrational trial of SRG-514 in triple-negative breast cancer this year.
12 Feb 2026 According to a Surge therapeutics media release, based on the data generated to date and discussions with the FDA, the company is preparing to advance SRG-514 directly into a registrational trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com